The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study
Schwizer W, Menne D, Schütze K, Vieth M, Goergens R, Malfertheiner P, Leodolter A, Fried M, Fox MR (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 1
Pages Range: 226-235
Journal Issue: 4
Abstract
Objectives: This study aimed to resolve controversy regarding the effects of Helicobacter pylori eradication therapy and H. pylori infection in gastro-oesophageal reflux disease. Design: A randomized, double-blind, multicentre trial was performed in patients presenting with reflux symptoms. H. pylori-positive patients were randomized to receive either antibiotics or placebo for 7 days. H. pylori-negative patient controls received placebo. All received esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. to complete an 8-week course, and were followed up for 32 weeks by telephone. Results: In this study, 198/589 (34%) patients were H. pylori-positive and 113 H. pylori-negative patients served as controls. Baseline endoscopy revealed 63% Los Angeles grade 0A and 37% Los Angeles grade BCD oesophagitis with no difference between patient groups. Symptom improvement on esomeprazole was seen in 89%. H. pylori eradication was successful in 82%. H. pylori eradication had no effect on symptomatic relapse (hazard ratio 1.15,95% CI 0.74-1.8; p = 0.5). Overall, H. pylori-positive patients had a lower probability of relapse compared to H. pylori-negative controls (hazard ratio 0.6, 95% CI 0.43-0.85; p = 0.004). Relapse hazard was modulated also by oesophagitis grade (BCD vs. 0A, hazard ratio 2.1, 95% CI 1.5-3.0). Conclusion: Relapse of gastro-oesophageal reflux disease symptoms after a course of high dose acid suppression took longer for H. pylori-positive patients than H. pylori-negative controls; however eradication therapy had no effect on the risk of relapse; ClincialTrials.gov number, NCT00574925.
Authors with CRIS profile
Involved external institutions
Universitätsspital Zürich (USZ)
Switzerland (CH)
Menne Biomed Consulting
Germany (DE)
Hanusch-Krankenhaus
Austria (AT)
Klinikum Bayreuth
Germany (DE)
Otto-von-Guericke-Universität Magdeburg
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Switzerland (CH)
Menne Biomed Consulting
Germany (DE)
Hanusch-Krankenhaus
Austria (AT)
Klinikum Bayreuth
Germany (DE)
Otto-von-Guericke-Universität Magdeburg
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
How to cite
APA:
Schwizer, W., Menne, D., Schütze, K., Vieth, M., Goergens, R., Malfertheiner, P.,... Fox, M.R. (2013). The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterology Journal, 1(4), 226-235. https://doi.org/10.1177/2050640613484020
MLA:
Schwizer, Werner, et al. "The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study." United European Gastroenterology Journal 1.4 (2013): 226-235.
BibTeX: Download